



BIOMM SA
Public Company
CNPJ/MF No. 04.752.991/0001-10
NIRE No. 31.300.016.510

NOTICE TO THE MARKET

BIOMM SA ("Company" or "Biommm"), in compliance with the provisions of Resolution of the Brazilian Securities Commission No. 44, of August 23, 2021, hereby informs its shareholders and the market in general that on the date hereof it entered into an agreement with Celltrion Healthcare Distribuição de Produtos Farmacêuticos do Brasil Ltda. ("Celltrion") for the distribution of the innovative drug of the active ingredient regdanvimab in the state of Minas Gerais, Brazil.

Regdanvimab is indicated for the treatment of patients diagnosed with COVID-19, who are hospitalized, in the mild and moderate stages of the disease and not requiring oxygenation and at high risk of progression to severe COVID-19. The drug had its emergency use approved by ANVISA - National Health Surveillance Agency on August 11, 2021.

Celltrion, headquartered in Incheon, South Korea (KOR), is a biopharmaceuticals company, listed in the South Korean market (KOSDAQ: 091990) and has already an exclusive partnership with Biommm for the commercialization of trastuzumab in the Brazilian private market.

Nova Lima/MG, October 14, 2021.

Mirna Santiago Vieira
Chief Financial and Investor Relations Officer